Literature DB >> 35344520

Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial.

Erica N Browne1, Elizabeth R Brown2,3, Thesla Palanee-Phillips4,5, Krishnaveni Reddy4, Logashvari Naidoo6, Nitesha Jeenarain6, Gonasagrie Nair7, Marla J Husnik2, Devika Singh8, Rachel Scheckter9, Lydia Soto-Torres10, Jared M Baeten11,12, Ariane van der Straten13,14.   

Abstract

BACKGROUND: Persistent use of HIV prevention methods can be a challenge, particularly for some younger women. The long-acting, discreet, woman-centric dapivirine vaginal ring offers promise as a prevention method with less user burden, which could support continued use. We assessed dapivirine vaginal ring use to understand adherence patterns and identify characteristics influencing patterns.
SETTING: Participants enrolled in South Africa in the MTN-020/ASPIRE randomized placebo-controlled trial.
METHODS: We used group-based trajectory modeling to identify clusters of participants with similar longitudinal patterns of adherence in the last year of participation and potential predictors of group membership. Women with at least 1 year of follow-up were included (n = 626).
RESULTS: Five adherence patterns were identified: (1) consistently high, 34%, (2) consistently moderate, 34%, (3) consistently low, 16%, (4) decreasing, 9%, and (5) increasing, 7%. Women younger than 22 years [adjusted odds ratio (AOR) 1.8, 95% confidence interval (CI): 1.0 to 3.0], using an intrauterine device (AOR 3.3, 95% CI: 1.4 to 7.8) or oral contraceptives (AOR 3.9, 95% CI: 1.7 to 8.9), experiencing menses (AOR 1.8, 95% CI: 1.1 to 3.0), and who reported inconsistent condom use (AOR 1.8, 95% CI: 1.0 to 3.3) were more likely to be classified as consistently low compared to consistently high (referent).
CONCLUSIONS: Most South African women successfully persisted with a moderate or high level of use. Encouraging ring replacement with completion of menses may help to decrease concerns about hygiene and improve persistence. Associations between contraception and persistent low adherence suggest efforts may be needed to ensure contraceptive method choice does not interfere with ring use.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35344520      PMCID: PMC9342948          DOI: 10.1097/QAI.0000000000002990

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  28 in total

1.  Group-based trajectory modeling in clinical research.

Authors:  Daniel S Nagin; Candice L Odgers
Journal:  Annu Rev Clin Psychol       Date:  2010       Impact factor: 18.561

2.  Group-based trajectory modeling: an overview.

Authors:  Daniel S Nagin
Journal:  Ann Nutr Metab       Date:  2014-11-18       Impact factor: 3.374

3.  Side effects from the copper IUD: do they decrease over time?

Authors:  David Hubacher; Pai-Lien Chen; Sola Park
Journal:  Contraception       Date:  2009-05       Impact factor: 3.375

4.  Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.

Authors:  Annalene Nel; Neliëtte van Niekerk; Saidi Kapiga; Linda-Gail Bekker; Cynthia Gama; Katherine Gill; Anatoli Kamali; Philip Kotze; Cheryl Louw; Zonke Mabude; Nokuthula Miti; Sylvia Kusemererwa; Hugo Tempelman; Hannelie Carstens; Brid Devlin; Michelle Isaacs; Mariëtte Malherbe; Winel Mans; Jeremy Nuttall; Marisa Russell; Smangaliso Ntshele; Marlie Smit; Leonard Solai; Patrick Spence; John Steytler; Kathleen Windle; Maarten Borremans; Sophie Resseler; Jens Van Roey; Wim Parys; Tony Vangeneugden; Ben Van Baelen; Zeda Rosenberg
Journal:  N Engl J Med       Date:  2016-12-01       Impact factor: 91.245

5.  Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.

Authors:  Thesla Palanee-Phillips; Sarah T Roberts; Krishnaveni Reddy; Vaneshree Govender; Logashvari Naidoo; Samantha Siva; Zakir Gafoor; Arendevi Pather; Flavia Matovu; Kudzai Hlahla; Bonus Makanani; Gonasagrie Nair; Katie Schwartz; Kristine Torjesen; Elizabeth Brown; Lydia Soto-Torres; Jared Baeten; Elizabeth T Montgomery
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-15       Impact factor: 3.731

Review 6.  HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery.

Authors:  Connie L Celum; Sinead Delany-Moretlwe; Jared M Baeten; Ariane van der Straten; Sybil Hosek; Elizabeth A Bukusi; Margaret McConnell; Ruanne V Barnabas; Linda-Gail Bekker
Journal:  J Int AIDS Soc       Date:  2019-07       Impact factor: 5.396

7.  Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial.

Authors:  Ashley J Mayo; Erica N Browne; Elizabeth T Montgomery; Kristine Torjesen; Thesla Palanee-Phillips; Nitesha Jeenarain; Linly Seyama; Kubashni Woeber; Ishana Harkoo; Krishnaveni Reddy; Tchangani Tembo; Prisca Mutero; Thelma Tauya; Miria Chitukuta; Brenda Gati Mirembe; Lydia Soto-Torres; Elizabeth R Brown; Jared M Baeten; Ariane van der Straten
Journal:  AIDS Behav       Date:  2021-03-13

8.  Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.

Authors:  Marla J Husnik; Elizabeth R Brown; Sufia S Dadabhai; Zakir Gaffoor; Nitesha Jeenarain; Flavia Matovu Kiweewa; Edward Livant; Leila E Mansoor; Brenda Gati Mirembe; Thesla Palanee-Phillips; Devika Singh; Samantha Siva; Lydia Soto-Torres; Ariane van der Straten; Jared M Baeten
Journal:  AIDS Behav       Date:  2021-06-11

9.  End-Users' Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa.

Authors:  Rachel Weinrib; Alexandra Minnis; Kawango Agot; Khatija Ahmed; Fred Owino; Kgahlisho Manenzhe; Helen Cheng; Ariane van der Straten
Journal:  AIDS Behav       Date:  2018-01

10.  Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.

Authors:  Elizabeth R Brown; Craig W Hendrix; Ariane van der Straten; Flavia M Kiweewa; Nyaradzo M Mgodi; Thesla Palanee-Philips; Mark A Marzinke; Linda-Gail Bekker; Lydia Soto-Torres; Sharon L Hillier; Jared M Baeten
Journal:  J Int AIDS Soc       Date:  2020-11       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.